Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.39 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078760 | 1.00 | CHUK (0.42) | CHUKGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL5075232 | 1.00 | CHUK (0.42) | CHUKGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL5635477 | 0.88 | PIM1 (0.41) | ADORA2AROCK2ROCK1 | |
| SCHEMBL5635759 | 0.88 | PIM1 (0.41) | ADORA2AROCK2ROCK1 | |
| SCHEMBL5635485 | 0.88 | PIM1 (0.41) | ADORA2AROCK2ROCK1 | |
| SCHEMBL14236197 | 0.80 | IRAK4 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1IRAK4 | |
| SCHEMBL5635534 | 0.80 | JAK3 (0.42) | JAK2 | |
| SCHEMBL5635925 | 0.80 | JAK3 (0.42) | JAK2 | |
| SCHEMBL5635543 | 0.80 | JAK3 (0.42) | JAK2 | |
| SCHEMBL5075075 | 0.79 | RPS6KA5 (0.41) | PIK3CDJAK2ROCK2SRCPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580802-B2 | Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2532667-A1 | Deazapurines useful as inhibitors of janus kinases | Vertex Pharmaceuticals Incorporated (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-B1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMA (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
| WO-2007041130-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CHUK 62/4885GUCY1B2 2133/4885GUCY1A2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.